Download - Sirona Biochem Fact Sheet jan.2016
Company Overview
Recent News • SBMReachesMajorMilestonewithSuccessfulScale-upofSkinLighteningCompoundSBM-TFC-1067
• SBMAnnouncesPositiveResultsofSBM-TFC-837Anti-agingRegenerativeandRegenerativeMedicine
• SBMCompletesExclusiveLicensingAgreementwithLeadingAnti-DiabeticCompanyinChina,WanbangBiopharmaceuticals
• SBMCompletesGlobalExclusiveLicensingAgreementwithObagiMedicalProducts/ValeantPharmaceuticals
• SBMAnnouncesJointVenturewithBloomBurton&Co.
• Proprietaryplatformtechnology• StrongIPportfolio• Riskdiversifiedbusinessmodel• Earlystagetechnologylicensing• Generatingrevenue• Award-winning• EUandFrenchGovernmentgrants
Stock InformationTSX-V:SBMFrankfurt/Xetra®:ZSB As of January 2016
• MarketCap:$25.5M• OutstandingShares:154M
Contact Information
Proprietary Platform TechnologyStabilizing carbohydrates for improved safety and efficacy
Management TeamDr.HowardVerrico,CEODr.GeraldineDeliencourt-Godefroy,CSOChristopherHopton,CFOAttilaHajdu,CBDOMichelleSeltenrich,VPOperations
SironaBiochemcautionsyouthatstatementsincludedinthisprofilethatarenotadescriptionofhistoricalfactsmaybeforward-lookingstatements.Forward-lookingstatementsareonlypredictionsbaseduponcurrentexpectationsandinvolveknownandunknownrisksanduncertainties.Youarecautionednottoplaceunduerelianceontheseforward-lookingstatements,whichspeakonlyasofthedateofreleaseoftherelevantinformation,unlessexplicitlystatedotherwise.Actualresults,performanceorachievementcoulddiffermateriallyfromthoseexpressedin,orimpliedby,SironaBiochem’sforward-lookingstatementsduetotherisksanduncertaintiesinherentinSironaBiochem’sbusinessincluding,withoutlimitation,statementsabout:theprogressandtimingofitsclinicaltrials;difficultiesordelaysindevelopment,testing,obtainingregulatoryapproval,producingandmarketingitsproducts;unexpectedadversesideeffectsorinadequatetherapeuticefficacyofitsproductsthatcoulddelayorpreventproductdevelopmentorcommercialization;thescopeandvalidityofpatentprotectionforitsproducts;competitionfromotherpharmaceuticalorbiotechnologycompanies;anditsabilitytoobtainadditionalfinancingtosupportitsoperations.SironaBiochemdoesnotassumeanyobligationtoupdateanyforward-lookingstatements.
Pharmaceutical Pipeline
SGLT2 Inhibitor
Anti-Inflammatory
Anti-Infective
Anti-Aging
Cosmetic Pipeline
ADVANCING CHEMISTRYENHANCING HEALTH
Pre-clinical
Chemistry / Patent Testing & Validation MarketSkin Lightening
Chemistry / Patent
Stage of DevelopmentProduct
Stage of DevelopmentProduct
Sirona Biochem is a cosmetic ingredient and drug discoverycompanywithaproprietaryplatformtechnology.Sironaspecializesin stabilizing carbohydratemoleculeswith the goal of improvingefficacy and safety.New compounds are patented formaximumrevenuepotential.
Sirona’s compounds are licensed to leading companies aroundtheworldinreturnforlicensingfees,milestonefeesandongoingroyaltypayments.Sirona’slaboratory,TFChem(locatedinFrance)istherecipientofmultipleFrenchscientificawardsandEuropeanUnionandFrenchgovernmentgrants.
twitter.com/sironabiochem
Value Proposition
StageAvailableforLicensing
Market
Pre-revenue
InRevenue
Pre-revenue
InRevenue
linkedin.com/company/sirona-biochem-corp.
facebook.com/pages/Sirona-Biochem-Corp/110521942342739
Social Media
Ph I Ph II Ph III
LicensingStatus
StageAvailableforLicensing
Clinical
LicensingStatus
Sirona Biochem CorpHeadOffice605-889WestPenderStreetVancouver,BC,V6C3B2Tel:604.641.4466TollFree:[email protected]
TFChemistry Laboratory-CosmeticValleyVoiedel’innovationPharmaParcIIChausséeduVexin27100ValdeReuilFranceTel:+33(0)2.32.09.01.16Fax:+33(0)2.32.25.07.64www.tfchemistry.com
SGLT2 Inhibitor
(China)
(ROW)*
*ROW-RestofWorld
-TFC-849-TFC-723-TFC-1067
